Summary Eighteen consecutive patients with measurable locally advanced or metastatic pancreatic adenocarcinoma were treated with goserelin (Zoladex) 3.6 mg subcutaneously every 4 weeks. Hydrocortisone 20 milligrams twice daily was commenced with the second injection of goserelin. Objective tumour response was monitored by computerised tomography of the abdomen. There was no objective remission in disease sites. Serial measurements of serum tumour markers showed no reduction in serum CA 19-9 and CA 195 concentrations. The median duration of survival of all cases was 5 months. Administration of goserelin resulted in significant reductions in oestradiol, testosterone, androstenedione in males and reductions in FSH and LH in both males and females. The addition of hydrocortisone resulted in further reductions of androstenedione and testosterone levels in males. Thus goserelin showed no anti-tumour effect, but concentrations required for direct inhibitory effects may be higher than those required to produce effects on hormone suppression.
Pancreatic carcinoma is increasing in incidence and represents a major cause of death due to cancer especially in middle aged men. Despite significant improvements in imaging techniques a substantial proportion of the patients present with advanced disease rendering radical surgery feasible in only 10-15% of the patients. Overall 5-year survival rates remain less than 1% and the majority of patients die within 6 months of diagnosis. The experience with cytotoxic therapy with or without radiotherapy in this disease has so far proved disappointing and is associated with appreciable toxicity because of the poor nutritional status and advanced age of many of these patients (Zimmerman, 1981) .
Epidemiologic data show that the age-adjusted incidence of pancreatic cancers is higher in males than females. It has long been known that human pancreatic tumour cells exhibit high concentrations of all three specific sex hormone receptors fulfilling a primary requirement for hormone responsiveness (Greenway et al., 1981; Corbishley et al., 1984; Corbishley et al., 1986) . Pousette et al. (1987) have also demonstrated the presence of high levels of human oestrogen binding protein in normal human pancreas and high to medium levels in human pancreatic cancer tissue. Testosterone levels in male patients with carcinoma of the pancreas are significantly lower than controls (Robles-Diaz, 1987) possibly due to the metabolism of testosterone within tumour cells. Two enzymes, aromatase and 5a-reductase, which convert testosterone to oestradiol and 5a-dihydro testosterone respectively, are present in malignant pancreatic tissue at a greater level than those found in normal pancreas (Iqbal et al., 1983) . Experimental work in animals has shown that testosterone stimulates and oestrogens inhibit the growth of pre-neoplastic pancreatic foci in male and female rats (Andren-Sandberg, 1989; Scarpelli & Konishi, 1990 (Szende et al., 1991) . No such binding sites were detected in normal pancreatic cells (Fekete et al., 1989 (Serrano et al., 1988 (Furr & Woodburn, 1988) and has been shown to be an effective therapy in premenopausal women with metastatic breast carcinoma and patients with prostatic carcinoma. Toxicity to goserelin is minimal and is predictable on the basis of hormonal deprivation. However, LHRH agonists do not produce total inhibition of sex hormone production because of the secretion of androgens by the adrenal glands. These adrenal androgens may be converted to oestrogens by peripheral aromatisation.
Replacement doses of hydrocortisone suppress the production of androgens from the adrenals which are also the major source of androgens in post-menopausal women . Therefore a combination of goserelin and hydrocortisone was used in this study in order to achieve maximal suppression of circulating androgens and oestrogens.
Accurate objective assessment of tumour response in pancreatic cancer is often difficult even with advanced imaging techniques. A number of serum markers have been proposed for the detection of pancreatic cancer and monitoring of disease progression. Approximately 87% of patients with pancreatic carcinoma exhibit elevated levels of serum CA 19-9 which correlates with tumour stage and burden (Safi et al., 1989) . CA 195 is another circulating tumour marker which shows high sensitivity for pancreatic cancer (Gupta et al., 1987) . Therefore assessment of response in this study was performed using both CT scanning and measurements of serum markers to identify minimal response.
The aims of this study were to assess the response of carcinoma of pancrease to therapy with goserelin plus hydro-cortisone and to determine the influence of such a hormonal treatment on the circulating hormone levels and serum tumour markers. Hydrocortisone was given after 1 month of goserelin to assess whether suppression of adrenal androgens would contribute significantly to androgen suppression already induced by goserelin.
Materials and methods

Patients
Eighteen patients with histologically or cytologically verified unresectable pancreatic adenocarcinoma were entered into this study. Clinical characteristics of the subjects are shown in Table I Assessment of response All patients were evaluated on a monthly basis with a physical examination and appropriate laboratory studies. CT scan of the abdomen and any other appropriate imaging tests were repeated 12 weekly and upon disease progression. Stable disease was defined as less than 25% increase in the size of assessable disease over a period of at least 12 weeks. An increase in the size of the measurable disease sites by greater than 25% indicated disease progression. Survival duration in months was measured from the start of treatment. Hormonal assessment The plasma concentrations of oestradiol, testosterone, androstenedione, FSH and LH were determined in ten patients using radioimmunoassay (Harris et al., 1982; Ferguson et al., 1982; Dowsett et al., 1984; Dowsett et al., 1987 
Results
Endocrine effects
Males (eight patients) Plasma testosterone, oestradiol, FSH, and LH concentrations were all suppressed below basal levels within 4 weeks of treatment (Table II) . The reduction in the concentration of androstenedione was also statistically significant (P = 0.2). The addition of hydrocortisone resulted in a further reduction of plasma testosterone levels (P = 0.05) with a statistically reduction in plasma androstenedione (P = 0.01). There was no significant reduction in either serum oestradiol (P = 0.7) or LH (P = 0.7) with hydrocortisone, whereas FSH levels slightly increased after treatment with hydrocortisone (P = 0.1).
Females (two patients) The two patients on whom endocrine assessment were made were aged 54 years and 67 years and were both post-menopausal. Treatment with goserelin resulted in reductions in only FSH and LH levels. Testosterone, androsternedione, and oestradiol levels were however no significantly altered following goserelin treatment. The addition of hydrocortisone resulted in no significant reduction of testosterone, androstenedione, oestradiol, LH and FSH levels.
Tumour response
Eight patients who had presented with obstructive jaundice underwent a surgical bypass procedure or endoscopic biliary stent insertion prior to commencing treatment. Two patients required urgent endoscopic relief of obstructive jaundice during therapy. The median number of courses of Zoladex received by the patients was three. Three patients showed stabilisation of the disease over a period of 9, 13 and 14 months respectively. The remainder of the patients developed tumour progression with the median duration of overall survival of 5 months (0.5 to 15 months).
Tumour markers Tumour markets measurements were undertaken in 14 patients. Ten patients had markedly significant elevation of (Fekete et al., 1989) . Carcinogen induced pancreatic tumours in hamsters showed a significantly greater response to the combination of somatostatin and LHRH agonist when compared to either drug administered on its own (Szende et al., 1990a) . It is therefore possible that hormonal stimulation may explain only one part of pancreatic tumourogenesis.
Given these results with goserelin plus hydrocortisone, the question remains whether hormonal therapy provides the alternative to chemotherapy in the treatment of advanced pancreatic carcinoma. Better understanding is needed on the contribution of hormonal and peptide growth regulation on the initiation and promotion of pancreatic carcinoma. To achieve this it may be necessary to test combinations of effective hormonal deprivation and modulators of mitogenic peptide hormone in the treatment of pancreatic tumours in man. New and more effective therapies are urgently required to meet this difficult cancer. Novel LHRH analogues may be investigated which are more potent or can achieve higher levels and have direct antitumour effects.
